Biosenta Commences TRUE(TM) Testing with Dynamic Facility Services

Biosenta begins real-world pilot of TRUE™ disinfectant with Dynamic, but no revenue yet.

What the company is saying

Biosenta Inc. is announcing the start of active, real-world testing for its TRUE™ disinfectant product in partnership with Dynamic Facility Services Ltd., following a previously announced pilot program. The company emphasizes that TRUE™ has now been deployed at two Dynamic-serviced locations—an office building and a commercial facility—to assess product fit within professional cleaning workflows. The narrative stresses the move from a Memorandum of Understanding to hands-on pilot testing, with the goal of generating frontline feedback and customer evidence that could support broader adoption. Both companies’ executives—Am Gill (President and CEO of Biosenta) and Justin Dhaliwal (Managing Director of Dynamic)—are quoted to highlight the importance of testing in operational environments and the potential for repeatable commercial use cases. The announcement is careful to clarify that there are no minimum purchase commitments or guaranteed revenue under the current MOU, and that any future adoption by Dynamic will depend on successful pilot results, Dynamic’s satisfaction, and a subsequent commercial agreement. The tone is measured, focusing on process, validation, and the conditional nature of any commercial outcome.

What the data suggests

The facts disclosed show that TRUE™ disinfectant is now being tested in two real-world settings with Dynamic Facility Services, specifically an office building and a commercial operation. This marks a shift from planning to execution, but no performance data, customer feedback, or commercial outcomes have been reported. The pilot is framed as a necessary step to validate product suitability, integration with existing cleaning protocols, and user experience, but results are pending. The MOU contains no minimum purchase or revenue guarantees, so there is no immediate financial impact or committed sales pipeline. The only quantifiable figures are the number of pilot sites (two), Dynamic’s nearly five decades of experience, and the September 1, 2026, pilot announcement date. The company’s commercialization strategy is described in process terms—engage, test, validate, qualify, secure purchase, expand—but remains unproven at this stage. All forward-looking statements are explicitly contingent on pilot success and subsequent negotiation.

Analysis

The announcement is factual and operational, describing the commencement of a commercial pilot for Biosenta's TRUE™ disinfectant with Dynamic Facility Services. The language is measured, focusing on the process and objectives of the pilot rather than making exaggerated claims about commercial success or financial impact. While there are forward-looking statements about potential broader adoption and commercial opportunities, these are clearly conditional on the pilot's outcome and do not overstate the likelihood of success. No financial figures, purchase commitments, or guaranteed revenue are disclosed, and the company explicitly notes that adoption depends on pilot results and further agreement. There is no evidence of narrative inflation or overstatement; the gap between narrative and evidence is minimal, as the company is transparent about the current stage and contingencies. The absence of capital outlay or immediate financial impact further supports a low hype assessment.

Risk flags

• ●There is no guaranteed revenue or minimum purchase commitment in the current MOU, so the pilot may not lead to any sales or recurring business. This leaves Biosenta exposed to the risk that Dynamic may choose not to adopt TRUE™ after testing, resulting in no financial benefit from the pilot.
• ●The announcement provides no data on product performance, customer satisfaction, or operational fit, so the commercial viability of TRUE™ remains unproven. Without clear evidence that the product delivers superior or differentiated value, broader adoption is speculative.
• ●Any future adoption by Dynamic is conditional on three factors: successful pilot completion, Dynamic’s satisfaction with results, and agreement on commercial terms. Each of these steps introduces execution risk, as failure at any stage would halt progress toward revenue.

Bottom line

Biosenta’s announcement signals that its TRUE™ disinfectant has moved from planning to real-world pilot testing with a credible commercial cleaning partner, Dynamic Facility Services, at two operational sites. The process is now generating frontline data, but there are no reported results, customer endorsements, or commercial agreements. The absence of minimum purchase commitments or guaranteed revenue means there is no immediate financial impact or sales pipeline. The credibility of the narrative is supported by clear disclosure of contingencies and the involvement of named executives, but the path to revenue remains entirely dependent on pilot outcomes and subsequent negotiation. Investors should focus on whether the pilot yields positive, quantifiable results and leads to a signed commercial agreement with Dynamic or other customers. The key takeaway is that this is an early-stage commercial test with all upside still to be proven.

Announcement summary

(CSE:ZRO) Biosenta Inc. has commenced testing of its TRUE™ disinfectant with Dynamic Facility Services Ltd., advancing the commercial pilot program previously announced on September 1, 2026. TRUE™ has been deployed at two locations serviced by Dynamic, specifically an office building and a commercial operation, to evaluate defined applications under real-world operating conditions. The pilot aims to assess how TRUE™ fits into professional cleaning workflows and to identify opportunities for broader commercial adoption. The testing moves Biosenta and Dynamic from an initial Memorandum of Understanding into active testing, generating frontline feedback and customer evidence that may support adoption by Dynamic. Biosenta intends to turn successful applications into repeatable use cases for prospective customers in professional cleaning, facility management, and institutional markets. The pilot will compare how TRUE™ fits different cleaning routines, application requirements, and end-user needs across the two sites. The evaluation will focus on product suitability, application requirements, integration with existing cleaning protocols, frontline user experience, and overall fit within professional cleaning operations. The goal is to identify where TRUE™ combines performance, practicality, and commercial value. Data, customer feedback, and implementation experience from the two sites may help Biosenta qualify additional opportunities and support discussions with commercial cleaning, facility-management, and institutional customers. Am Gill, President and CEO of Biosenta Inc., stated that moving TRUE™ into operating facilities allows the company to test more than product performance and to identify where TRUE™ fits existing cleaning workflows and which applications create the strongest customer value. Justin Dhaliwal, Managing Director of Dynamic Facility Services, commented that testing TRUE™ in two facility settings will help assess how it fits Dynamic's cleaning processes and where it may provide meaningful value to operations and customers. Biosenta's commercialization strategy involves engaging a customer, testing TRUE™ in real operating conditions, validating a defined use case, qualifying the commercial opportunity, securing a purchasing decision, and, where successful, expanding deployment. The MOU between Biosenta and Dynamic does not contain minimum purchase commitments or guaranteed revenue. Any adoption by Dynamic will depend on successful completion of the pilot, Dynamic's satisfaction with the results, and agreement between the parties on applicable commercial terms. Successful validation could advance procurement and implementation discussions with Dynamic and provide reference applications for pursuing additional customers. TRUE™ is a disinfectant product developed and commercialized by Biosenta Inc., with product efficacy and use claims subject to applicable regulatory approvals, product labelling, and supporting evidence.

Disagree with this article?